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Somatic mutation of the tumor suppressor gene TP53 is reported in at least 50% of human malignancies.
Most high-grade serous ovarian cancers (HGSC) have a mutant TP53 allele. Accurate detection of these
mutants in heterogeneous tumor tissue is paramount as therapies emerge to target mutant p53. We used a
Fluidigm Access Array™ System with Massively Parallel Sequencing (MPS) to analyze DNA extracted from
76 serous ovarian tumors. This dataset has been made available to researchers through the European
Genome-phenome Archive (EGA; EGAS00001002200). Herein, we present analyses of this dataset using
HaplotypeCaller and MuTect2 through the Broad Institute’s Genome Analysis Toolkit (GATK). We anticipate
that this TP53 mutation dataset will be useful to researchers developing and testing new software to
accurately determine high and low frequency variant alleles in heterogeneous aneuploid tumor tissue.
Furthermore, the analysis pipeline we present provides a valuable framework for determining somatic
variants more broadly in tumor tissue.
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Background & Summary
The tumor suppressor gene TP53 is the most frequently mutated gene in somatic cells of human cancers,
with mutant TP53 identified in over 50% of tumors1–5. While wild-type p53 acts to suppress a
tumorigenic phenotype, both loss-of-function and oncogenic gain-of-function (GOF) TP53 mutations
promote tumorigenesis. In some tumors, such as high-grade serous ovarian cancers (HGSCs) TP53
mutation is an early event, likely occurring in precursor lesions6–9. In colorectal cancer, mutation of TP53
can occur as a relatively late event in a multistep tumorigenic pathway that progresses from
hyperproliferative cells in colonic epithelium, through colorectal adenomas and finally metastatic
colorectal cancer10,11. Germline mutation of TP53 is associated with Li-Fraumeni syndrome where
carriers are predisposed to develop malignancies including early onset breast cancer, brain and
adrenocortical tumours, leukemia and soft tissue sarcoma12. Whether a mutation occurs in a single allele
in the germline associated with increased risk of familial syndromes, or in sporadic cancers in somatic
tissue where timing of its emergence may be different along the tumor progression pathway, has the
potential to influence its frequency in tumor tissue.
There is a large and growing interest in targeting mutant p53 for cancer therapy13–15, resulting in a
concomitant need to accurately detect the presence of a TP53 mutation. This was the driving motivation
for the original manuscript, i.e., to develop methodologies to accurately identify somatic TP53 mutation
in HGSC that could be used to triage women with this malignancy into appropriate trials targeting
specific forms of mutant p5316. While the detection of a germline mutation in DNA extracted from a
blood sample is relatively straightforward using the established method of Sanger sequencing, the
detection of somatic DNA variants in tumor tissue, especially those occurring at low frequency, can pose
challenges. Reasons for this include the heterogeneous nature of tumor tissue as the result of expansion of
clonal populations and factors such as the presence of non-neoplastic cells, as well as aneuploidy,
originating from tumor-associated phenomenon such as chromosomal instability17.
Massively parallel sequencing (MPS) of tumor tissue for variant detection in single genes of interest to
the exclusion of either a cohort of other genes or the entire genome, is not broadly supported by current
technologies in a cost effective manner. The Fluidigm Access Array System, specifically the Access Array
BRCA1/BRCA2/TP53 Target-Specific Panel (Fluidigm, South San Francisco, CA, USA) coupled with
MPS, was a cost effective way to achieve our goal of generating comprehensive MPS data for TP53 in
DNA extracted from a moderately sized cohort of primary ovarian tumors.
Here, we present a detailed analysis of TP53 MPS data using two software programs embedded within
the Broad Institute’s Genome Analysis Toolkit (GATK), specifically HaplotypeCaller and MuTect2.
HaplotypeCaller was specifically designed for the detection of germline mutations, although numerous
papers have used this software for somatic variant calling16,18–21. MuTect2 has been designed to detect a
range of variant allele frequencies, as described below. TP53 variants identified by HaplotypeCaller were
also screened for using Sanger sequencing and this data is presented. A schematic overview of this study,
including bioinformatic pipelines, is presented (Fig. 1).
The dataset described herein offers a cohort on which to further develop robust methodologies and
pipelines for determining a range of frequencies of somatic variants in tumor tissue that, by its very
nature, is often heterogeneous and driven by genomic events resulting in aneuploidy. Data has been
generated using DNA extracted from a cohort of HGSC (N= 72) that is recognized as a genomically
complex malignancy with extensive chromosomal abnormalities22. Given that a large study from The
Cancer Genome Atlas (TCGA) reported over 96% of HGSC with a somatic TP53 mutation22, there was
an expectation that TP53 mutation should be identified in the vast majority of HGSCs in this cohort.
Somatic TP53 mutation is not a feature of low-grade serous ovarian cancers (LGSC)23, of which four are
included here and in the original study16.
Methods
This section includes, and expands upon, the Methods outlined in our earlier manuscript16. When
reference is made to previously published figures or tables (including Supplementary Data), the identifier
is preceded by ‘OM’ denoting from the ‘Original Manuscript’. Methods, samples and datasets are outlined
in the Experimental Study Table.
Study cohort
Seventy-two HGSCs and four LGSCs collected from between 2004–2014 at three hospitals (Royal North
Shore Hospital, North Shore Private and The Mater Hospital—North Sydney, Sydney, Australia) were
analyzed for this study (Supplementary Table OM-S3). Advanced stage HGSCs (Stage III or IV) made up
the majority of this cohort (82%; 59/72). Written informed patient consent was obtained as per our ethics
protocol (Protocol: 108–243M, approved by the Northern Sydney Local Health District Human Research
Ethics Committee). All tumors were snap frozen in liquid nitrogen and stored in the Kolling Institute of
Medical Research (KIMR) Gynecological Tumor Bank until required.
Tumor DNA preparation
DNA was extracted from approximately 30 mg of fresh frozen tumor tissue. Tissue was homogenised in
50 μl phosphate buffered saline (PBS) until liquefied using two glass beads with shaking three times for
90 s each time at the highest frequency in a Retsch MM 301 Mixer Mill (MEP Instruments Pty. Ltd.,
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NSW, Australia). Protein was digested at 56 °C overnight with 20 μl of proteinase K (20 mgml−1) (Qiagen
Pty Ltd, Chadstone, VIC, Australia). DNA was extracted using the DNeasy Blood and Tissue Kit in an
automated system (QIAcube; Qiagen Pty Ltd, Chadstone, VIC, Australia). DNA concentration was
determined using Qubit Fluorometric Quantitation, specifically using the Qubit dsDNA BR Assay Kit
(Life Technologies Australia Pty. Ltd., Mulgrave, VIC, Australia). A NanoDrop ND-1000 spectro-
photometer (Thermo Fisher Scientific Australia, Scoresby, VIC, Australia) was used to determine 260:280
and 260:230 ratios.
Fluidigm access array and massively parallel sequencing (MPS) of tumor DNA to identify
somatic TP53 mutations
As described in the original manuscript16, DNA extracted from tumors was processed for MPS using the
Access Array BRCA1/BRCA2/TP53 Target-Specific Panel (Fluidigm, South San Francisco, CA, USA).
The 48.48 Access Array integrated fluidic circuits (IFC) was used, including target specific primers
containing a common sequence tag (CS1 or CS2) and Illumina adaptors PE1 and PE2. Samples were
identified by a sample specific barcode located on the reverse sequence (PE1_CS1 Forward
Primer, 5′-AATGATACGGCGACCACCGAGATCTACACTGACGACATGGTTCTACA-3′, 47 bp;
PE2_BC_CS2 Reverse primer, 5′-CAAGCAGAAGACGGCATACGAGAT [sample specific barcode]
TACGGTAGCAGAGACTTGGTCT-3′, 56 bp). This system uses 16 primer pairs generating amplicons
of between 191–209 base pairs to enable 92% coverage of TP53 exons.
Five μl of DNA (50 ng μl−1) was added to the array and processed on the Fluidigm Biomark HD Real-
Time PCR fluidics system according to the manufacturer’s guidelines by the Ramaciotti Centre for
Genomics (University of New South Wales, Randwick, Australia). Amplicon libraries were pooled and a
single MPS run was performed on a MiSeq platform using Miseq Control Software (MCS) version 2.4.1
(Illumina Inc., San Diego, CA, USA).
Figure 1. Overview of workflow and bioinformatic pipelines employed in this study.
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MPS data analysis and processing with HaplotypeCaller software
Sequencing data was received in FASTQ file format and adaptors trimmed using cutadapt
(http://cutadapt.readthedocs.io/en/stable/guide.html). Trimmed FASTQ files were then aligned to the
human genome (hg19) using Burrows-Wheeler Aligner (BWA) 0.7.10 and ‘known-indel’ realignment
and recalibration which is embedded in the Broad Institute’s Genome Analysis Toolkit (GATK) Queue
3.2–2 data processing pipeline. The TP53 gene region (chr17:7,569,720–7,592,868) was extracted from
BAM files using samtools (http://samtools.sourceforge.net). At the time of publication of the original
manuscript16, HaplotypeCaller was the variant analysis software embedded into the GATK best practice
pipeline (GATK 3.2–2; https://www.broadinstitute.org/gatk/guide/best-practices). HaplotypeCaller
assumes that DNA is from a diploid organism. It is best suited to germline variant calling; however, is
able to detect allele frequencies outside of an expected 50:50 ratio. Annotation of variant calls was
performed using ANNOVAR, version 2013J24.
Each sample summary was imported into Excel and filtered to display TP53 variants, excluding
intronic variants other than the canonical splice sites. Filtering criteria were applied to remove reads with
a quality (QUAL) score less than 100. TP53 variants were further filtered based on their frequency in the
1,000 Genome Database (Phase 3 integrated, all population, updated August2015)25. If a particular
variant occurred at a frequency greater than 10% in this database, the variant was deemed to be non-
deleterious and excluded from the analysis. Lastly, variants were filtered based on SIFT scores (Sorting
Intolerant From Tolerant; from dbNSFP v3.0 that amalgamates SIFT to the version based on Ensembl 66.
For release 66, Ensembl ran SIFT version 4.0.5 using UniProtKB [release 2012_01, both the SwissProt and
TrEMBL sets]). SIFT is an in silico tool for predicting the functional effects of a variant on the associated
protein26. Variants predicted to be tolerated were excluded. All remaining variants were considered
deleterious or did not have a SIFT score and were visualized using the Integrative Genomics Viewer (IGV,
v2.3, www.broadinstitute.org)27,28. The allele frequency of each mutation was recorded upon visualization
of the mutation via IGV. This analysis pipeline was previously summarized (Supplementary Fig. OM-S5).
MPS data processing and analysis with MuTect2 software
Since publication of the original manuscript16, MuTect2 has become available through GATK that
combines aspects of the original MuTect29 and HaplotypeCaller for somatic genotyping. MuTect2 detects
a range of allele frequencies, making it eminently more suitable for somatic genotyping in heterogeneous,
often aneuploid, tumor tissue compared to HaplotypeCaller that was designed for germline variant calling
where alleles are present in equal ratios. FASTQ files were trimmed and aligned as described for
HaplotypeCaller. Somatic variant calling was performed using MuTect2 beta in GATK version 3.6. The
four LGSCs (previously shown to be wild-type for TP53 using identical MPS and analysis pipelines to the
HGSCs studied; Supplementary Table OM-S2) were combined into a Panel of Normals (PoN) variant
cohort against the Single Nucelotide Polymorphism database current build 138 (dbsnp138) and COSMIC
coding mutations. Tumor only variant-calling was then performed using the pre-generated PoN for each
tumor sample. MuTect2 software requires a minimum of two samples to create a PoN variant call format
(VCF) file. Each tumor VCF was annotated using ANNOVAR (2016Feb01; http://annovar.open-
bioinformatics.org/en/latest/) and merged into an Excel spreadsheet for downstream analyses.
The PoN calls were removed, as were low quality calls (defined as having a theta-logarithm of the
Odds (TLOD)o6.3). Synonymous variant calls were filtered out along with variants in intronic and
Figure 2. Mutant alleles identified by HaplotypeCaller. (a) Schematic representation of the proportion of
tumor samples in our cohort in which different frequencies of variant alleles were detected. Color coding
represents the frequency of variant alleles within individual samples. (b) Correlation between mutant allele
frequency in tumor tissue and percent tumor cell composition. Tumor percentage was plotted against TP53
mutant allele frequency for 67 HGSC samples and the R2 value determined (R2= 0.3917).
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untranslated regions. Non-deleterious calls were filtered out based on SIFT scores as above. Variant calls
not occurring within the full length transcript (TP53:NM_000546) or canonical splice sites were also
removed. Lastly, a manual filter was applied to remove variant calls occurring at a frequency of less
than 5%.
Code availability
All tools required for the analysis of this data are freely available. Instructions for downloading and
installation are in scripts.sh (https://figshare.com/articles/scripts_sh/4542397).
1. wget to retrieve BAM files (binary version of tab-delimited text files containing sequence alignment
data and the recommended format for IGV) from the online EGA web server that has archived
this data.
2. GATK for somatic variant calling in tumor samples can be performed using Mutect2 as part of the
GATK pipeline.
3. ANNOVAR to annotate variant information to prioritize somatic variant calling.
The requirements for running GATK and ANNOVAR can be referenced from each website
respectively. Analysis scripts (bash shell code) should be run in the MacOS/Unix system by opening
~ /Applications/Utilities/Terminal.app.
For re-analysis of data, registration will be required for GATK version 3.6 (https://figshare.com/
articles/GenomeAnalysisTK_jar/4541719) and ANNOVAR (2016Feb01). The file named ‘script.sh’
(https://figshare.com/articles/scripts_sh/4542397) will need to be downloaded in which the section uses
‘/path/to/’ in order to indicate paths that should be modified by the user depending on the location the
data files are to be downloaded to. Certain files will require download as compressed files that will need
decompression and setting of a path to the executable file. Script pipelines may take 22 h to run on a 4
cores, 16 GB personal computer. All file downloads will require 34 GB of storage space.
Data Record
TP53MPS data (Data Citation 1) is available in the European Genome-phenome Archive (EGA) with the
study accession number EGAS00001002200 and dataset accession number EGAD00001003119 (Table 1
(available online only)). This dataset contains MPS information on 76 unique tumor samples from
individual patients, of which four are LGSCs and 72 are HGSCs. All sample files are in the BAM format
and have been extracted to have the p53 gene (TP53) region reads along with the unmapped reads.
Technical Validation
Quality control—assessment of percentage tumor cells in each sample
A pathologist [AJG] reviewed all tumor tissue in order to confirm diagnosis, histological grade and
pathological stage. Sequential sections from frozen tumors were analyzed to determine percent tumour
cells after staining with hematoxylin and eosin. For inclusion in this study, tumors were required to
contain a minimum of 5% tumor cells. The percent tumor cell composition in samples used in this study
ranged from 5–90% (Supplementary Table OM-S1).
Quality control—DNA integrity
Prior to analysis on the Fluidigm Access Array, DNA integrity was assessed using the Qubit dsDNA BR
Assay Kit for fluorimetric quantitation. This assay is selective for double-stranded DNA (dsDNA) over
RNA and is designed for optimal performance within a concentration range of 100 pg–1,000 ng μl−1.
Based on this quantitation, DNA was diluted to 50 ng μl−1 using nuclease and PCR inhibitor free elution
buffer EA from the QIAamp DNA Mini Kit (Qiagen Pty Ltd). DNA was confirmed to be clean by
assessment of 260:280 and 260:230 ratios >1.8 using the NanoDrop.
Quality control -massively parallel sequencing (MPS) data and analysis
As described in the original manuscript, amplicon libraries for 72 samples were generated using the
Access Array BRCA1/BRCA2/TP53 Target-Specific Panel (Fluidigm, South San Francisco, CA, USA),
pooled and sequenced in a single run on a MiSeq platform using Miseq Control Software (MCS) version
2.4.1 (Illumina Inc., San Siego, CA, USA)16. This single sequencing run produced a cluster density of
1,133±31 K/MM2 (84.57%± 1.89 passing filter) and 20,626,284 sequence reads (17,452,900 passing filter)
with 95.42% ≥Q30 (Read 1) and 92.61% ≥Q30 (Read 2).
Described in methods, analysis of MPS data, using both HaplotypeCaller and MuTect2, required
extensive filtering to remove reads of poor quality, variants that appeared in datasets of normal genomes
and variants predicted to be non-pathogenic. Filtering protocols are summarized in Fig. 1 as part of our
bioinformatics analysis pipeline. The allele frequency for TP53 mutations called by MPS using
HaplotypeCaller ranged from 13–92% in the HGSC cohort (mean and median values 55 and 54%
respectively; Supplementary Table OM-S1 and Fig. 2a). The TP53 mutant allele frequency for a single
sample with a large in-frame insertion (#880–13 [c.723_724dupACCATCCACTACAACTACATGTG-
TAACAGTTCC]; Supplementary Table OM-S1) was unable to be determined with our analysis pipeline,
although was detectable by Sanger sequencing.
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We assessed whether the percent tumor cell composition was likely to influence the frequency of the
mutant alleles that were detected. These two variables were graphed, a line of best fit plotted and the R2
value calculated (Fig. 2b). This analysis demonstrated a small correlation (R2= 0.3917) between these two
variables, suggesting that our minimum criteria of 5% tumor cell composition was adequate for detecting
TP53 variants using our pipeline. Any concerns regarding potential influence of a low percentage of
tumor cells could be circumvented by the use of tumor macro- or micro-dissection to ensure a more pure
cancer cell population for analysis30.
Re-analysis of our data with MuTect2 (beta) resulted in identification of all of the variants detected by
HaplotypeCaller, with one exception discussed below, and an additional five TP53 variants with allele
frequencies ranging from approximately 2–3% (Table 2). We excluded these variants by setting a manual
filter for all frequencies below 5%. It is unclear whether these low frequency variants are artefacts
introduced by MuTect2 software, or indeed represent very low frequency somatic TP53 mutations in
sporadic tumors. We do not have further access to these specimens to investigate them with alternative
methodology such as digital PCR that may detect very low frequency variant alleles. If these low
frequency variants are not artefacts, their biological significance in the tumor milieu is unclear. The
possibility that MuTect2 software can detect very low frequency alleles in heterogeneous cell populations
may be of relevance in some malignancies where active screening for early relapse and/or response to
therapy is undertaken. Furthermore, analyses with MuTect2 showed the allele frequency of the large in-
frame insertion (#880-13; Supplementary Table OM-S1) as 0.5%. Given that we could easily visualize this
mutation using Sanger sequencing that we showed in the original manuscript16 could not reliably detect
variants at allele frequencies less than 25%, it is not possible that this insertion is present at such a low
frequency in this tumor. This data suggests that care should be taken when using MuTect2 to identify
variants involving larger alterations.
Usage Notes
The following gives clear instructions as to how to apply to access the dataset described in this
manuscript.
Use the search bar on the front page of the European Genome-Phenome Archive website (https://ega-
archive.org/) to search for this study with a keyword such as ‘TP53’ or the study ID number that is
EGAS00001002200. This will bring you to a screen where you can view information on datasets, data
providers, data access committees (DACs) and any other documentation associated with this study.
A description of this study is located under the heading ‘Study Description’. There is a single dataset
associated with this study (Study ‘Datasets 1 dataset’ and its data ID number is EGAD0001003119. Click
on this dataset ID to take you to information about who to contact regarding access to this data.
Each dataset in EGA is affiliated to a Data Access Committee (DAC), which is the group responsible
for data access decisions following a formal application process. Access to actual data files is not managed
by the EGA. You must apply to this DAC to gain access to this controlled dataset using your EGA
account. Upon clicking on the dataset ID, you will come to the heading ‘Who controls access to this
dataset’. For requests to access this dataset, please contact:
DAC: Functional Genomics Laboratory, Kolling Institute of Medical Research DAC—TP53 mutation
data in ovarian cancer.
Contact Person: Deborah Marsh
Email: deborah [dot] marsh [at] Sydney [dot] edu [dot] au
More details: EGAC00001000589
A Data Access Agreement (DAA) will be required. The DAA is a contract between the proposed user
of the data and the DAC. This will contain information such as details of data use, publication embargoes
and storage of data. Completion of a DAA by the applicant(s) should be considered as part of the
application process to the DAC. A template DAA can be found on the EGA website under ‘Policy
documentation—Data Access Agreement (DAA)’. A modified template specific for this dataset is




















5 c.490A>G Lys164Glu 2929:58 0.02 D Yes 70
198-08 17:7577541–7577541 T(97%):
C(3%)
7 c.740A>G Asn247Ser 2336:60 0.026 D Yes 10
198-08 17:7579471–7579471 G(97%):
− (3%)
4 c.216delC Pro72Argfs*49 2116:56 0.026 N/A No 10
206-08 17:7577556–7577556 C(98%):
G(2%)
7 c.725G>C Cys242Ser 2334:53 0.023 D Yes 50
427-09 17:7577574–7577574 T(97%):
C(3%)
7 c.707A>G Try236Cys 2003:59 0.029 D Yes 80
Table 2. Additional TP53 variants identified by MuTect2 at low frequency. ^D, Deleterious;
N/A, no SIFT call; *IARC, International Agency for Research on Cancer.
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provided as Supplementary Data. The completed EGA DAA signed by both parties (the data provider
and those wishing to access the data) should be emailed to ega-helpdesk@ebi.ac.uk.
Upon receiving the completed DAA approved by the DAC, EGA will arrange a one-time login to set a
password for your EGA account that will be sent to your email address. Following authorisation of your
password, you will receive email notification that your EGA account is ready for your use. A list of the
datasets you have been granted access to will appear on your ‘My Datasets’ page in EGA. From here, you
will be able to download the data.
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